This study is testing alanyl-glutamine, a supplement, alongside standard treatment for Clostridioides difficile infection (CDI). CDI is a bacterial infection that causes diarrhea and inflammation of the colon. Researchers want to find the best dose of alanyl-glutamine to reduce how often CDI comes back and to improve patient outcomes. You might be able to join if you are 18 or older, have CDI, and are being treated at UVA or Carilion hospitals, or as an outpatient at UVA. The study will look at whether alanyl-glutamine helps prevent CDI from returning within 60 days after treatment.

Study design

This is a Phase II, randomized, double-blind, placebo-controlled study with 260 participants. Participants will be divided into four groups, receiving different doses of alanyl-glutamine or a placebo.

What's involved

You would take alanyl-glutamine or a placebo orally once a day for 10 days. You will have daily check-ups during treatment and weekly check-ups for 60 days after treatment.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed weekly for 60 days after treatment to check for recurrences and survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.